{
    "abstract": "Radioligand therapy is a targeted cancer treatment modality in which radioisotopes are utilized in the delivery of radiation at targeted cancer cells, with the goal of sparing normal cells. Prostate cancer is a well-known radiosensitive disease, historically treated with radioisotopes such as Strontium-89, Samarium-153, and Radium-223 for palliation of bone metastases. Recently, prostate specific membrane antigen (PSMA) has recently been employed as a radioligand target due to its unique properties of high expression on the surface of prostate cancer cells, limited expression in normal tissue, function as an internalizing cell surface receptor, and increased expression with androgen deprivation therapy. In 2015, ",
    "authors": [
        {
            "affiliation": "Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.",
            "firstname": "Alexander",
            "initials": "A",
            "lastname": "Konopnicki"
        },
        {
            "affiliation": "Department of Urology, University of California San Francisco, San Francisco, CA, USA.",
            "firstname": "Michael",
            "initials": "M",
            "lastname": "Zaliznyak"
        },
        {
            "affiliation": "Department of Internal Medicine, University of Texas Medical Branch, Galveston, TX, USA.",
            "firstname": "Mathews",
            "initials": "M",
            "lastname": "Roy"
        },
        {
            "affiliation": "Department of General Oncology, The University of Texas MD Anderson Cancer Center, Houston, TX, 77030, USA. brjana@utmb.edu.",
            "firstname": "Bagi",
            "initials": "B",
            "lastname": "Jana"
        }
    ],
    "conclusions": null,
    "copyrights": "\u00a9 2024. The Author(s).",
    "doi": "10.1007/s12672-024-01680-z",
    "journal": "Discover oncology",
    "keywords": [
        "177Lu-PSMA-617",
        "Prostate Cancer",
        "Radioligand therapy"
    ],
    "methods": null,
    "publication_date": "2024-12-18",
    "pubmed_id": "39692806\n31811257\n26773820\n33533204\n8478230\n15134985\n24836273\n31362406\n28663195\n9751609\n28878845\n25573634\n34161051\n32310541\n33056955\n31068988\n28434181\n12050481\n19198621\n10801170\n31983834\n28578639\n31329516\n31157964\n35179323\n24881730\n30763142\n29420164\n21612468\n23228172\n22894553\n25199761\n20888992\n21448449\n33581798\n27765862\n29752180\n31732676\n31789908\n39293462\n9610707\n27660139\n9763084\n22056152\n20933466\n24027196\n24027197\n34430419\n30521067\n27104782\n31401014\n30890448\n31099652\n35454924\n37922930\n34028967\n38621400\n34494131\n37883619\n36469000",
    "results": null,
    "title": "The therapeutic use of 177 Lu-PSMA-617 radioligand therapy in prostate cancer treatment: a review of literature and ongoing trials.",
    "xml": "<Element 'PubmedArticle' at 0x788503f08fe0>"
}